Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 92.37% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 151.28% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -99.90% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -12.04% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 327.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 95.87% |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -110.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.76% |
| Mar 31, 2026 | 63.40% |
| Dec 31, 2025 | 284.50% |
| Sep 30, 2025 | 128.47% |
| Jun 30, 2025 | 431.75% |
| Mar 31, 2025 | -16.42% |
| Dec 31, 2024 | -192.80% |
| Sep 30, 2024 | -41.88% |
| Jun 30, 2024 | -5.65% |
| Mar 31, 2024 | 46.22% |
| Dec 31, 2023 | -236.18% |
| Sep 30, 2023 | -100.97% |
| Jun 30, 2023 | -185.12% |
| Mar 31, 2023 | -239.10% |
| Dec 31, 2022 | -84.90% |
| Sep 30, 2022 | 4,400.00% |
| Jun 30, 2022 | 47.61% |
| Mar 31, 2022 | 128.92% |
| Dec 31, 2021 | 134.26% |
| Sep 30, 2021 | 127.98% |